Volume 16 Number 6 (March 15th, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Chemotherapy Foundation Symposium, November 7-10, 2007, New York
Nonmyeloablative Alogeneic Transplants Ready for Prime-Time in Follicular Lymphoma?
Allogeneic transplantation is now a good option for treating some patient groups with follicular lymphoma. David Maloney explained to Peter Goodwin in Paris how his group has harnessed graft-versus-tumor effect by using nonmyeloablative conditioning without causing unacceptable risks of graft-versus-host disease.
Trabectedin Activity in Platinum-Sensitive Relapsed Ovarian Cancer
Could trabectedin, which has a novel mechanism of action, be a useful agent for patients with relapsed ovarian cancer? Derek Thorne discussed this question in New York with Carolyn Krasner, whose data show the greatest benefit in patients who are sensitive to platinum agents.
High-Dose Chemotherapy Plus Imatinib Benefits Pediatric Acute Lymphoblastic Leukemia
COMMENT: Armand Keating, Princess Margaret Hospital, Toronto
For children with acute lymphoblastic leukemia, high-dose chemotherapy combined with imatinib appears to show a survival benefit. Sarah Maxwell spoke with study author Kirk Schultz at the ASH meeting in Atlanta, and Armand Keating provided comment.
Chronic Lymphocytic Leukemia: New Options After Fludarabine Failure
New treatments for chronic lymphocytic leukemia were discussed in Paris by John Gribben. He gave Peter Goodwin his assessment of antibody therapies such as rituximab and alemtuzumab and new drugs such as lenalidomide, and combinations including standard fludarabine therapy.